RESCUE was a randomized, double-blind, placebo-controlled phase 2 trial evaluating RNS60 as an adjunct therapy in large vessel occlusion (LVO) acute ischemic stroke patients undergoing endovascular thrombectomy.
RNS60 was safe and well tolerated with no increase in serious adverse events or mortality compared with placebo.
The higher dose of RNS60 (1.0 mL/kg/h) reduced infarct volume growth by 47% at 48 hours after thrombectomy versus placebo.
Although other functional outcomes did not reach statistical significance, trends suggested improved neurological recovery and functional independence favoring RNS60 1.0 mL/kg/h at 90 days.
